Fresenius Medical Care

Mark your calendars and join our Fresenius Medical Care Expert Call on High-Volume Hemodiafiltration (HDF). Gain insights into HDF therapy from a medical perspective and meet Frank Maddux MD, FACP, our Global Chief Medical Officer and member of the Management Board. The call will take place on September 16, 2024, at 3:00 PM CEST / 9:00 AM EDT Find more information via the link: https://lnkd.in/diT93Qrh #InvestorRelations #ExpertCalls #Dialysis #HDF #ProudToBeFME

Join us in celebrating the occasion! To all nephrology nurses working to improve patient outcomes and provide life-saving care – thank you, for your unwavering commitment. Your work is essential and has a profound impact for patients and families alike. We are grateful for the difference you make every day. #NephrologyNursesWeek #RenalCare #ProudToBeFME

It was great to be back on the road and meet investors. Thank you to Robert J Davies, PhD and Aisyah N. to host Fresenius Medical Care CEO Helen Giza at the 22nd Annual Morgan Stanley Global Healthcare Conference in New York. #investorrelations #proudtobeFME

High-volume hemodiafiltration (HDF) continues to show superior outcomes compared to traditional hemodialysis (HD) for patients with end-stage kidney disease. The CONVINCE study found that high-volume HDF significantly reduces all-cause mortality, particularly infection-related deaths, and improves patient-reported outcomes. These findings suggest that HDF can offer a survival advantage over and above conventional HD, reinforcing its growing role in dialysis treatment. In the latest episode of GMO Dialogues, Dr. Giovanni Strippoli, Professor of Nephrology at the Università degli Studi di Bari and Adjunct Professor of Epidemiology at University of Sydney, discusses the pivotal findings of the CONVINCE study, sharing valuable insights into how these findings may influence future dialysis practices for patients with end-stage kidney disease. Watch the latest episode now and dive into the benefits of HDF: https://lnkd.in/deFa7GHi #GMODialogues #CONVINCEStudy #MedicalResearch #Dialisys

I am thrilled to share that Fitch Ratings has upgraded Fresenius Medical Care's Rating Outlook to stable and affirmed our investment grade rating. This change follows similar moves by the rating agencies S&P Global and Moody's earlier this year. The stable outlook reflects our improved operational and financial performance throughout 2023 and the first half of 2024, our strengthened balance sheet and the progress of our FME25 transformation program. With restoring our credit metrics and a stringent capital allocation, we are committed to maintain our investment grade rating, while continuing to execute on our mid-term plans. Read more in Fitch Ratings related press release: Fitch Revises Fresenius Medical Care's Outlook to Stable; Affirms at 'BBB-' (https://lnkd.in/edarAShG). #Ratings #InvestmentGrade #Treasury #ProudToBeFME

As we published Fresenius Medical Care’s second quarter 2024 earnings this morning, I’m proud to share we have maintained our momentum following our good start to the year, delivering continued operating income improvements. In light of the developments in the first half of the year, we confirm our financial outlook for the full year 2024. I am immensely grateful for our team’s dedication and hard work in achieving these results. We continue to deliver on our turnaround and transformation efforts. However, there is still work to be done. In 2024, we are executing with discipline. We are well-positioned to drive growth, cost discipline and efficiencies in the coming quarters. A special thank you to Ulrich Reitz from ntvNachrichten and also to CNBC for having us this morning to talk about our financial performance, as well as all the journalists in today’s media call. It was a pleasure talking with you all! For more information on our earnings, read today’s press release here: https://lnkd.in/dzBXypeh #Reporting #EarningsRelease #QuarterlyReport #Q22024 #InvestorRelations #ProudToBeFME

News📢: Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024. Check out our Q2 earnings we released today.   Operating income and operating income margin increase is driven by our MedTech segment Care Enablement while Care Delivery, our global network of dialysis clinics and services, finalized further divestments of several assets in our international operations. Our organic revenue growth of +2.3% is supported by both segments Care Delivery and Care Enablement. Additional #FME25 savings of EUR 57 million achieved in Q2 2024, and on track to reach the upper end of the full year savings target range. We reduced financial debt further and confirm our financial outlook for the full year 2024.   Quote CEO Helen Giza: “In the second quarter, we further improved our financial performance while executing against our strategic plan and the company transformation. This quarter is another important proof point for the operational turnaround as we remain focused to deliver on our targets.”   Read more in our press release here: https://lnkd.in/dh_Sfm-b #Reporting #EarningsRelease #QuarterlyReport #Q22024 #InvestorRelations

Patients who dialyze at home often experience greater independence and an improved quality of life compared to in-center patients, thanks to the flexibility to manage their treatment on their own schedule. However, home dialysis also comes with its own set of challenges. In our latest episode of GMO Dialogues, Michelle Carver, Chief Nursing Officer and Senior Vice President of Nursing and Clinical Services at Fresenius Kidney Care, explains in an insightful conversation about the transformative potential of home dialysis for people living with kidney disease. Watch the full episode to discover more about the benefits and barriers of dialyzing at home. #GMODialogues #HomeDialysis #PatientEmpowerment

Mark your calendars! 📅 On July 30th, Fresenius Medical Care plans to release this year’s second quarter earnings. #SaveTheDate to be among the first to read our press release! #Reporting #EarningsRelease #QuarterlyReport #Q22024 #InvestorRelations

This year, Fresenius Medical Care’s St. Wendel plant celebrates its 50th anniversary! Since its founding in 1974, this manufacturing site, located in Saarland, Germany, has grown into one of the world's largest production and export sites for dialyzers, and one of the most important global technology centers for Fresenius Medical Care. With more than 1,000 patents having been registered at the site since its inception, the site has developed into a leading center of innovation and quality in dialyzer manufacturing. "It is the outstanding spirit of innovation that has made St. Wendel what it is today and has helped make dialysis treatment more effective and accessible for patients worldwide." says Dr. Katarzyna Mazur-Hofsäß, Member of the Management Board of FME and responsible for the Care Enablement segment, the MedTech division. It's been a journey of innovation and dedication to improving patient care and our innovation is inextricably linked with this manufacturing site. St. Wendel has been the birthplace of significant scientific breakthroughs that continue to positively influence our patients' lives today. Join us in celebrating the 50th anniversary tomorrow and explore a collection of photos showcasing the incredible journey and the dedicated team behind its success. 🌟 Read more in the press release here: https://lnkd.in/dSzFVvKP #TogetherAhead #ProudtobeFME #Dialysis #HealthcareInnovation